2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 461

Etanercept Has a Better Retention Rate at 10 Years Than Adalimumab in Patients with Rheumatoid Arthritis. Results from Rhumadata®: A Real-Life Clinical Database and Registry
Abstract Number: 2850

Etanercept Treatment in Psoriatic Arthritis: Need for Co-Medication?
Abstract Number: 643

Ethnicity of Sjögren’s Syndrome
Abstract Number: 1506

EULAR Recommendations for Cardiovascular Risk Management in Patients with Rheumatoid Arthritis and Other Inflammatory Joint Diseases – 2015 Update
Abstract Number: 485

Evaluate the Dose Efficacy Response Relationship of Baricitinib in Patients with Rheumatoid Arthritis
Abstract Number: 1296

Evaluating Inter-Rater Reliability in Joint Count to Promote Quality and Trust in a Clinical Arthritis Care Team
Abstract Number: 2755

Evaluating Pharmacokinetic Predictors of Tofacitinib Clinical Response in Rheumatoid Arthritis
Abstract Number: 76

Evaluating Weather’s Effect on Fibromyalgia Patients Using the Revised Fibromyalgia Impact Questionnaire and the Brief Pain Inventory
Abstract Number: 853

Evaluation and Validation of Case-Finding Algorithms for the Identification of Patients with Granulomatosis with Polyangiitis in Large Healthcare Administrative Databases
Abstract Number: 3065

Evaluation and Validation of Case-Finding Algorithms for the Identification of Patients with Takayasu’s Arteritis in Large Healthcare Administrative Databases
Abstract Number: 3244

Evaluation of a Self-Directed Walking Program in Hispanics with Arthritis
Abstract Number: 2663

Evaluation of Anti-Cyclic Citrullinated Peptide Autoantibody Levels in Clinical Practice and Its Association with Disease Activity
Abstract Number: 1657

Evaluation of Bone and Joint Proteins for Prognostic Association with Radiographic Progression and Disease Activity in Methotrexate Inadequate Responder Rheumatoid Arthritis Patients in a Sarilumab Phase 3 Study
Abstract Number: 1524

Evaluation of Changes in Cardiovascular Risk Factors Among Patients with RA Prescribed Biologic Dmards
Abstract Number: 2310

Evaluation of Fibromyalgia Syndrome in Patients Undergoing Peritoneal Dialysis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].